An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020

Daniel C Santana, Ahmed K Emara, Melissa N Orr, Alison K Klika, Carlos A Higuera, Viktor E Krebs, Robert M Molloy, Nicolas S Piuzzi, Daniel C Santana, Ahmed K Emara, Melissa N Orr, Alison K Klika, Carlos A Higuera, Viktor E Krebs, Robert M Molloy, Nicolas S Piuzzi

Abstract

Patients undergoing total hip and knee arthroplasty are at high risk for venous thromboembolism (VTE) with an incidence of approximately 0.6-1.5%. Given the high volume of these operations, with approximately one million performed annually in the U.S., the rate of VTE represents a large absolute number of patients. The rate of VTE after total hip arthroplasty has been stable over the past decade, although there has been a slight reduction in the rate of deep venous thrombosis (DVT), but not pulmonary embolism (PE), after total knee arthroplasty. Over this time, there has been significant research into the optimal choice of pharmacologic VTE prophylaxis for individual patients, with the objective to reduce the rate of VTE while minimizing adverse side effects such as bleeding. Recently, aspirin has emerged as a promising prophylactic agent for patients undergoing arthroplasty due to its similar efficacy and good safety profile compared to other pharmacologic agents. However, there is no evidence to date that clearly demonstrates the superiority of any given prophylactic agent. Therefore, this review discusses (1) the current prevalence and trends in VTE after total hip and knee arthroplasty and (2) provides an update on pharmacologic VTE prophylaxis in regard to aspirin usage.

Keywords: DVT; arthroplasty; joint replacement; pulmonary embolism; surgical complications; venous thromboembolism.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall rates of venous thromboembolism (VTE), deep venous thrombosis (DVT), and pulmonary embolism (PE) after total hip arthroplasty. Data points represent values reported by individual studies at the start and end of the study period. When there was no statistically significant difference over time, the average value is shown for both the beginning and end of the study period. References: [6,9,37,38,39,42,43,44].
Figure 2
Figure 2
Overall rates of venous thromboembolism (VTE), deep venous thrombosis (DVT), and pulmonary embolism (PE) after total knee arthroplasty. Data points represent values reported by individual studies at the start and end of the study period. When there was no statistically significant difference over time, the average value is shown for both the beginning and end of the study period. References: [6,9,37,39,43,44,47,48].

References

    1. Lespasio M.J., Piuzzi N.S., Husni M.E., Muschler G.F., Guarino A., Mont M.A. Knee osteoarthritis: A primer. Perm. J. 2017;21:1–7. doi: 10.7812/TPP/16-183.
    1. Lespasio M.J., Sultan A.A., Piuzzi N.S., Khlopas A., Husni M.E., Muschler G.F., Mont M.A. Hip osteoarthritis: A primer. Perm. J. 2018;22:89–94. doi: 10.7812/TPP/17-084.
    1. Santana D.C., Anis H.K., Mont M.A., Higuera C.A., Piuzzi N.S. What is the likelihood of subsequent arthroplasties after primary TKA or THA? Data from the osteoarthritis initiative. Clin. Orthop. Relat. Res. 2020;478:34–41. doi: 10.1097/CORR.0000000000000925.
    1. Sloan M., Premkumar A., Sheth N.P. Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030. J. Bone Jt. Surg. 2018;100:1455–1460. doi: 10.2106/JBJS.17.01617.
    1. Kremers H.M., Larson D.R., Crowson C.S., Kremers W.K., Washington R.E., Steiner C.A., Jiranek W.A., Berry D.J. Prevalence of total hip and knee replacement in the United States. J. Bone Jt. Surg. 2014;97:1386–1397. doi: 10.2106/JBJS.N.01141.
    1. Shahi A., Chen A.F., Tan T.L., Maltenfort M.G., Kucukdurmaz F., Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J. Arthroplast. 2017;32:1063–1066. doi: 10.1016/j.arth.2016.10.020.
    1. Dai W.-L., Lin Z.-M., Shi Z.-J., Wang J. Venous thromboembolic events after total knee arthroplasty: Which patients are at a high risk? J. Knee Surg. 2019;1 doi: 10.1055/s-0039-1688962.
    1. Warren J.A., Sundaram K., Kamath A.F., Molloy R.M., Krebs V.E., Mont M.A., Piuzzi N.S. Venous thromboembolism rates did not decrease in lower extremity revision total joint arthroplasty from 2008 to 2016. J. Arthroplast. 2019;34:2774–2779. doi: 10.1016/j.arth.2019.05.012.
    1. Warren J.A., Sundaram K., Anis H.K., Kamath A.F., Higuera C.A., Piuzzi N.S. Have venous thromboembolism rates decreased in total hip and knee arthroplasty? J. Arthroplast. 2020;35:259–264. doi: 10.1016/j.arth.2019.08.049.
    1. White R.H., Zhou H., Romano P.S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb. Haemost. 2003;90:446–455.
    1. Wells P.S., Hirsh J., Anderson D.R., Lensing A.W.A., Foster G., Kearon G.F., Weitz J., D’Ovidio R., Cogo A., Prandoni P., et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995;345:1326–1330. doi: 10.1016/S0140-6736(95)92535-X.
    1. Hirsh J., Hull R.D., Raskob G.E. Clinical features and diagnosis of venous thrombosis. J. Am. Coll. Cardiol. 1986;8:114B–127B. doi: 10.1016/S0735-1097(86)80013-4.
    1. Myers D., Farris D., Hawley A., Wrobleski S., Chapman A., Stoolman L., Knibbs R., Strieter R., Wakefield T. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J. Surg. Res. 2002;108:212–221. doi: 10.1006/jsre.2002.6552.
    1. Righini M., Le Gal G., De Lucia S., Roy P.-M., Meyer G., Aujesky D., Bounameaux H., Perrier A. Migration of dendritic cells across blood and lymphatic endothelial barriers. Thromb. Haemost. 2006;95:715–719.
    1. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic risk factors (THRIFT) consensus group. BMJ. 1992;305:567–574. doi: 10.1136/bmj.305.6853.567.
    1. Agu O., Hamilton G., Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br. J. Surg. 1999;86:992–1004. doi: 10.1046/j.1365-2168.1999.01195.x.
    1. Snyder M.A., Sympson A.N., Scheuerman C.M., Gregg J.L., Hussain L.R. Efficacy in deep vein thrombosis prevention with extended mechanical compression device therapy and prophylactic aspirin following total knee arthroplasty: A randomized control trial. J. Arthroplast. 2017;32:1478–1482. doi: 10.1016/j.arth.2016.12.027.
    1. Nakamura M., Kamei M., Bito S., Migita K., Miyata S., Kumagai K., Abe I., Nakagawa Y., Nakayama Y., Saito M., et al. Spinal anesthesia increases the risk of venous thromboembolism in total arthroplasty: Secondary analysis of a J-PSVT cohort study on anesthesia. Medicine. 2017;96:e6748. doi: 10.1097/MD.0000000000006748.
    1. Bergen M.A., Wall K.C., Kim C.Y., Garrigues G.E. Occult left common iliac vein compression increases postoperative venous thromboembolism risk following total hip arthroplasty. J. Arthroplast. 2019;34:375–378. doi: 10.1016/j.arth.2018.10.024.
    1. Frank B., Maher Z., Hazelton J.P., Resnick S., Dauer E., Goldenberg A., Lubitz A.L., Smith B.P., Saillant N.N., Reilly P.M., et al. Venous thromboembolism after major venous injuries: Competing priorities. J. Trauma Acute Care Surg. 2017;83:1095–1101. doi: 10.1097/TA.0000000000001655.
    1. Roth-Isigkeit A., Borstel T.V., Seyfarth M., Schmucker P. Perioperative serum levels of tumour-necrosis-factor alpha (TNF-α), IL- 1β, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution. Clin. Exp. Immunol. 1999;118:242–246. doi: 10.1046/j.1365-2249.1999.01050.x.
    1. Neumaier M., Metak G., Scherer M.A. C-reactive protein as a parameter of surgical trauma: CRP response after different types of surgery in 349 hip fractures. Acta Orthop. 2006;77:788–790. doi: 10.1080/17453670610013006.
    1. Dahl O.E., Harenberg J., Wexels F., Preissner K.T. Arterial and venous thrombosis following trauma and major orthopedic surgery: Molecular mechanisms and strategies for intervention. Semin. Thromb. Hemost. 2015;41:141–145.
    1. Albayati M.A., Grover S.P., Saha P., Lwaleed B.A., Modarai B., Smith A. Postsurgical inflammation as a causative mechanism of venous thromboembolism. Semin. Thromb. Hemost. 2015;41:615–620. doi: 10.1055/s-0035-1556726.
    1. Wanderling C., Liles J., Finkler E., Carlsgaard P., Hopkinson W., Guler N., Hoppensteadt D., Fareed J. Dysregulation of tissue factor, thrombin-activatable fibrinolysis inhibitor, and fibrinogen in patients undergoing total joint arthroplasty. Clin. Appl. Thromb. 2017;23:967–972. doi: 10.1177/1076029617700998.
    1. Kim Y., Park Y., Joo Y., Kim S.Y., Kim J. The role of platelet hyperreactivity in venous thromboembolism after total knee arthroplasty in elderly population without pharmacologic prophylaxis: A single-center study. Int. J. Lab. Hematol. 2019;41:102–108. doi: 10.1111/ijlh.12932.
    1. Rumbaut R.E., Thiagarajan P. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. Morgan & Claypool Life Sciences; San Rafael, CA, USA: 2010.
    1. Morris G.K., Henry A.P.J., Preston B.J. Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement. Lancet. 1974;304:797–800. doi: 10.1016/S0140-6736(74)91069-1.
    1. Sharnoff J.G., DeBlasio G. Prevention of fatal postoperative thromboembolism by heparin prophylaxis. Lancet. 1970;296:1006–1007. doi: 10.1016/S0140-6736(70)92815-1.
    1. Gallus A.S., Hirsh J., Tuttle R.J., Trebilcock R., O’Brien S.E., Carroll J.J., Minden J.H., Hudecki S.M. Small subcutaneous doses of heparin in prevention of venous thrombosis. N. Engl. J. Med. 1973;288:545–551. doi: 10.1056/NEJM197303152881103.
    1. Pellegrini V.D., Jr., Clement V., Lush-Ehmann C., Keller G.S., McCollister Evarts C. Natural history of thromboembolic disease after total hip arthroplasty. Clin. Orthop. Relat. Res. 1996;333:27–40. doi: 10.1097/00003086-199612000-00004.
    1. Fender D., Harper W.M., Thompson J.R., Gregg P.J. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J. Bone Jt. Surg. Br. 1997;79:896–899. doi: 10.1302/0301-620X.79B6.0790896.
    1. Etzioni D.A., Lessow C., Bordeianou L.G., Kunitake H., Deery S.E., Carchman E., Papageorge C.M., Fuhrman G., Seiler R.L., Ogilvie J., et al. Venous thromboembolism after inpatient surgery in administrative data vs NSQIP: A multi-institutional study. J. Am. Coll. Surg. 2018;226:796–803. doi: 10.1016/j.jamcollsurg.2018.01.053.
    1. Ni J., Dasgupta K., Kahn S.R., Talbot D., Lefebvre G., Lix L.M., Berry G., Burman M., Dimentberg R., Laflamme Y., et al. Comparing external and internal validation methods in correcting outcome misclassification bias in logistic regression: A simulation study and application to the case of postsurgical venous thromboembolism following total hip and knee arthroplasty. Pharmacoepidemiol. Drug Saf. 2019;28:217–226. doi: 10.1002/pds.4693.
    1. Yeomans D., Todd F.S., Whitehouse M.R., Matharu G.S. Can we use routinely collected healthcare data for a nationwide trial on venous thromboembolism prophylaxis following primary joint replacement? a feasibility study. J. Arthroplast. 2020;35:1983–1985. doi: 10.1016/j.arth.2020.03.033.
    1. Groff H., Azboy I., Parvizi J. Differences in reported outcomes in industry-funded vs nonfunded studies assessing thromboprophylaxis after total joint arthroplasty. J. Arthroplast. 2018;33:3398–3401. doi: 10.1016/j.arth.2018.06.025.
    1. Dua A., Desai S.S., Lee C.J., Heller J.A. National trends in deep vein thrombosis following total knee and total hip replacement in the united states. Ann. Vasc. Surg. 2017;38:310–314. doi: 10.1016/j.avsg.2016.05.110.
    1. Lieberman J.R., Cheng V., Cote M.P. Pulmonary embolism rates following total hip arthroplasty with prophylactic anticoagulation: Some pulmonary emboli cannot be avoided. J. Arthroplast. 2017;32:980–986. doi: 10.1016/j.arth.2016.09.006.
    1. Pedersen A.B., Mehnert F., Sorensen H.T., Emmeluth C., Overgaard S., Johnsen S.P. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: A 15-year retrospective cohort study of routine clinical practice. Bone Jt. J. 2014;96-B:479–485. doi: 10.1302/0301-620X.96B4.33209.
    1. Lee S., Hwang J.I., Kim Y., Yoon P.W., Ahn J., Yoo J.J. Venous thromboembolism following hip and knee replacement arthroplasty in Korea: A nationwide study based on claims registry. J. Korean Med. Sci. 2016;31:80–88. doi: 10.3346/jkms.2016.31.1.80.
    1. Januel J.M., Romano P.S., Couris C.M., Hider P., Quan H., Colin C., Burnand B., Ghali W.A. Clinical and health system determinants of venous thromboembolism event rates after hip arthroplasty an international comparison. Med. Care. 2018;56:862–869. doi: 10.1097/MLR.0000000000000959.
    1. Grosso M.J., Neuwirth A.L., Boddapati V., Shah R.P., Cooper H.J., Geller J.A. Decreasing length of hospital stay and postoperative complications after primary total hip arthroplasty: A decade analysis from 2006 to 2016. J. Arthroplast. 2019;34:422–425. doi: 10.1016/j.arth.2018.11.005.
    1. Fuji T., Akagi M., Abe Y., Oda E., Matsubayashi D., Ota K., Kobayashi M., Matsushita Y., Kaburagi J., Ibusuki K., et al. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: A retrospective analysis of a Japanese healthcare database. J. Orthop Surg. Res. 2017;12:1–9. doi: 10.1186/s13018-017-0549-4.
    1. Zeng Y., Si H., Wu Y., Yang J., Zhou Z., Kang P., Pei F., Shen B. The incidence of symptomatic in-hospital VTEs in Asian patients undergoing joint arthroplasty was low: A prospective, multicenter, 17,660-patient-enrolled cohort study. Knee Surg. Sport Traumatol. Arthrosc. 2019;27:1075–1082. doi: 10.1007/s00167-018-5253-3.
    1. Courtney P.M., Boniello A.J., Levine B.R., Sheth N.P., Paprosky W.G. Are revision hip arthroplasty patients at higher risk for venous thromboembolic events than primary hip arthroplasty patients? J. Arthroplast. 2017;32:3752–3756. doi: 10.1016/j.arth.2017.07.028.
    1. Gionis M.N., Ioannou C.V., Katsamouris A.N., Katonis P., Balalis K., Sfyridaki K., Elalamy I., Gerotziafas G.T. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. Thromb. Res. 2013;132:685–691. doi: 10.1016/j.thromres.2013.09.037.
    1. Sarpong N.O., Boddapati V., Herndon C.L., Shah R.P., Cooper H.J., Geller J.A. Trends in length of stay and 30-day complications after total knee arthroplasty: An analysis from 2006 to 2016. J. Arthroplast. 2019;34:1575–1580. doi: 10.1016/j.arth.2019.04.027.
    1. Cote M.P., Chen A., Jiang Y., Cheng V., Lieberman J.R. Persistent pulmonary embolism rates following total knee arthroplasty even with prophylactic anticoagulants. J. Arthroplast. 2017;32:3833–3839. doi: 10.1016/j.arth.2017.06.041.
    1. Hart A., Antoniou J., Brin Y.S., Huk O.L., Zukor D.J., Bergeron S.G. Simultaneous bilateral versus unilateral total knee arthroplasty: A comparison of 30-day readmission rates and major complications. J. Arthroplast. 2016;31:31–35. doi: 10.1016/j.arth.2015.07.031.
    1. Bagsby D., Pierson J.L. Functional outcomes of simultaneous bilateral versus unilateral total knee arthroplasty. Orthopedics. 2015;38:e43–e47. doi: 10.3928/01477447-20150105-59.
    1. Masrouha K.Z., Hoballah J.J., Tamim H.M., Sagherian B.H. Comparing the 30-day risk of venous thromboembolism and bleeding in simultaneous bilateral vs unilateral total knee arthroplasty. J. Arthroplast. 2018;33:3273–3280. doi: 10.1016/j.arth.2018.06.002.
    1. Boylan M.R., Perfetti D.C., Kapadia B.H., Delanois R.E., Paulino C.B., Mont M.A. Venous thromboembolic disease in revision vs primary total knee arthroplasty. J. Arthroplast. 2017;32:1996–1999. doi: 10.1016/j.arth.2016.12.051.
    1. Chan N.C., Siegal D., Lauw M.N., Ginsberg J.S., Eikelboom J.W., Guyatt G.H., Hirsh J. A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: Suggestions for a radical reappraisal. J. Thromb. Thrombolysis. 2015;40:231–239. doi: 10.1007/s11239-014-1153-7.
    1. Xu K., Chan N.C., Ibrahim Q., Kruger P., Sinha S., Bhagirath V., Ginsberg J., Bangdiwala S., Guyatt G., Eikelboom J., et al. Reduction in mortality following elective major hip and knee surgery: A systematic review and meta-analysis. Thromb. Haemost. 2019;119:668–674. doi: 10.1055/s-0039-1677732.
    1. Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., Ortel T.L., Pauker S.G., Colwell C.W. Prevention of VTE in Orthopedic Surgery Patients. Antithrombotic Therapy and Prevention Of Thrombosis, 9th ed; In American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S–e325S. doi: 10.1378/chest.11-2404.
    1. American Academy of Orthopaedic Surgeons . Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty: Evidence-Based Guideline and Evidence Report. 2nd ed. American Academy of Orthopaedic Surgeons; Rosemont, IL, USA: 2011. p. 850.
    1. Randelli F., Cimminiello C., Capozzi M., Bosco M., Cerulli G. Real life thromboprophylaxis in orthopedic surgery in Italy. Results of the GIOTTO study. Thromb. Res. 2016;137:103–107. doi: 10.1016/j.thromres.2015.11.007.
    1. Farfan M., Bautista M., Bonilla G., Rojas J., Llinás A., Navas J. Worldwide adherence to ACCP guidelines for thromboprophylaxis after major orthopedic surgery: A systematic review of the literature and meta-analysis. Thromb. Res. 2016;141:163–170. doi: 10.1016/j.thromres.2016.03.029.
    1. Runner R.P., Gottschalk M.B., Staley C.A., Pour A.E., Roberson J.R. utilization patterns, efficacy, and complications of venous thromboembolism prophylaxis strategies in primary hip and knee arthroplasty as reported by american board of orthopedic surgery part ii candidates. J. Arthroplast. 2019;34:729–734. doi: 10.1016/j.arth.2018.12.015.
    1. Mirkazemi C., Bereznicki L.R., Peterson G.M. Comparing Australian orthopaedic surgeons’ reported use of thromboprophylaxis following arthroplasty in 2012 and 2017. BMC Musculoskele. Disord. 2019;20:1–11. doi: 10.1186/s12891-019-2409-3.
    1. Kim S., Ahn H., Shin S.-A., Park J.-H., Won C.W. Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National health insurance claim data. Thromb. Res. 2017;155:48–52. doi: 10.1016/j.thromres.2017.04.023.
    1. Kim N.K., Kim T.K., Kim J.M., Chun C.H. Prophylaxis for venous thromboembolism following total knee arthroplasty: A survey of korean knee surgeons. Knee Surg. Relat. Res. 2016;28:207–212. doi: 10.5792/ksrr.2016.28.3.207.
    1. Yhim H.Y., Lee J., Lee J.Y., Lee J.O., Bang S.M. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study. PLoS ONE. 2017;12:e0178214. doi: 10.1371/journal.pone.0178214.
    1. Bin Abd Razak H.R., Binte Abd Razak N.F., Tan H.C.A. Prevalence of venous thromboembolic events is low in asians after total knee arthroplasty without chemoprophylaxis. J. Arthroplast. 2017;32:974–979. doi: 10.1016/j.arth.2016.09.008.
    1. Chang M.J., Chang C.B., Yoon C., Shin J.-H., Song M.K., Kim S.J., Choi S.H., Song Y.J., Kang S.-B. Incidence of deep vein thrombosis before and after tka without pharmacologic prophylaxis: A 128-row multidetector CT indirect venography study. Asia Pac. J. Sport Med. Arthrosc. Rehabil. Technol. 2017;9:18. doi: 10.1016/j.asmart.2017.05.017.
    1. Matharu G.S., Kunutsor S.K., Judge A., Blom A.W., Whitehouse M.R. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 2020;180:376–384. doi: 10.1001/jamainternmed.2019.6108.
    1. Anderson D.R., Dunbar M., Murnaghan J., Kahn S.R., Gross P., Forsythe M., Pelet S., Fisher W., Belzile E., Dolan S., et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N. Engl. J. Med. 2018;378:699–707. doi: 10.1056/NEJMoa1712746.
    1. Farey J.E., An V.V.G., Sidhu V., Karunaratne S., Harris I.A. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. Orthop. Traumatol. Surg. Res. 2020:1–9. doi: 10.1016/j.otsr.2020.04.002.
    1. Rondon A.J., Shohat N., Tan T.L., Goswami K., Huang R.C., Parvizi J. The use of aspirin for prophylaxis against venous thromboembolism decreases mortality following primary total joint arthroplasty. J. Bone Jt. Surg. 2019;101:504–513. doi: 10.2106/JBJS.18.00143.
    1. Goel R., Fleischman A.N., Tan T., Sterbis E., Huang R., Higuera C., Parvizi J., Rothman R.H. Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: Aspirin versus warfarin. Bone Jt. J. 2018;100-B(Suppl. A):68–75. doi: 10.1302/0301-620X.100B1.BJJ-2017-0587.R1.
    1. Tan T.L., Foltz C., Huang R., Chen A.F., Higuera C., Siqueira M., Hansen E.N., Sing D.C., Parvizi J. Potent anticoagulation does not reduce venous thromboembolism in high-risk patients. Bone Jt. J. 2019;101:589–599. doi: 10.2106/JBJS.18.00335.
    1. Azboy I., Groff H., Goswami K., Vahedian M., Parvizi J. Low-dose aspirin is adequate for venous thromboembolism prevention following total joint arthroplasty: A systematic review. J. Arthroplast. 2020;35:886–892. doi: 10.1016/j.arth.2019.09.043.
    1. Faour M., Piuzzi N.S., Brigati D.P., Klika A.K., Mont M.A., Barsoum W.K., Higuera C.A. Low-dose aspirin is safe and effective for venous thromboembolism prophylaxis following total knee arthroplasty. J. Arthroplast. 2018;33:S131–S135. doi: 10.1016/j.arth.2018.03.001.
    1. Faour M., Piuzzi N.S., Brigati D.P., Klika A.K., Mont M.A., Barsoum W.K., Higuera C.A. No Difference between low- and regular-dose aspirin for venous thromboembolism prophylaxis after THA. Clin. Orthop. Relat. Res. 2019;477:396–402. doi: 10.1097/CORR.0000000000000613.
    1. Bonutti P.M., Sodhi N., Patel Y.H., Sultan A.A., Khlopas A., Chughtai M., Kolisek F.R., Williams N., Mont M.A. Novel venous thromboembolic disease (VTED) prophylaxis for total knee arthroplasty-aspirin and fish oil. Ann. Transl. Med. 2017;5(Suppl. 3):2–7. doi: 10.21037/atm.2017.11.22.
    1. Vaz K.M., Brown M.L., Copp S.N., Bugbee W.D. Aspirin used for venous thromboembolism prophylaxis in total hip arthroplasty decreases heterotopic ossification. Arthroplast. Today. 2020;6:206–209. doi: 10.1016/j.artd.2020.01.010.
    1. Sidhu V.S., Graves S.E., Buchbinder R., Naylor J.M., Pratt N.L., de Steiger R.S., Chong B.H., Ackerman I.N., Adie S., Harris A., et al. CRISTAL: Protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study. BMJ Open. 2019;9:1–9. doi: 10.1136/bmjopen-2019-031657.
    1. Comparative Effectiveness of Pulmonary Embolism Prevention after Hip and Knee Replacement (PEPPER) [(accessed on 20 July 2020)]; Available online: .
    1. Moreno J.P., Bautista M., Castro J., Bonilla G., Llinás A. Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study. Int. Orthop. 2020;44:237–243. doi: 10.1007/s00264-019-04454-3.
    1. Najafzadeh M., Kim S.C., Patterson C., Schneeweiss S., Katz J.N., Brick G.W., Ready J.E., Polinski J.M., Patorno E. Patients’ perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: A qualitative study. BMC Musculoskele. Disord. 2015;16:4–11. doi: 10.1186/s12891-015-0777-x.
    1. Wittig-Wells D., Higgins M., Carter J., Davis E., Holmes E., Jacob A., Samms-Mcpherson J., Simms S. Impact of a preset daily cell phone alarm on medication adherence for aspirin as antithrombotic therapy. Orthop. Nurs. 2019;38:311–316. doi: 10.1097/NOR.0000000000000592.
    1. Wiznia D.H., Swami N., Nguyen J., Musonza E., Lynch C., Gibson D., Pelker R. Patient compliance with deep vein thrombosis prophylaxis after total hip and total knee arthroplasty. Hematol. Rep. 2019;11:30–33. doi: 10.4081/hr.2019.7914.
    1. Wittig-Wells D., Shapiro S., Higgins M., Samms-Mcpherson J., Winterboer D.S., Johnson I., Carter J., Jacob A. Self-reported rates of adherence to aspirin prescribed as an antithrombotic therapy following postoperative total joint replacement. Orthop. Nurs. 2017;36:287–292. doi: 10.1097/NOR.0000000000000367.
    1. Parvizi J., Huang R., Rezapoor M., Bagheri B., Maltenfort M.G. Individualized risk model for venous thromboembolism after total joint arthroplasty. J. Arthroplast. 2016;31:180–186. doi: 10.1016/j.arth.2016.02.077.
    1. Benjamin S., Warwick D. Venous thromboembolism after total knee replacement or total hip replacement: What can be learnt from root-cause analysis? Ann. R. Coll. Surg. Engl. 2016;98:538–542. doi: 10.1308/rcsann.2016.0202.
    1. Kahn S.R., Shivakumar S. What’s new in VTE risk and prevention in orthopedic surgery. Res. Pract. Thromb. Haemost. 2020;4:366–376. doi: 10.1002/rth2.12323.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere